Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Meropenem-vaborbactam restoration of first-line drug efficacy and comparison of meropenem-vaborbactam-moxifloxacin versus BPaL MDR-TB regimen

Published:2023-12 Issue:6 Volume:62 Page:106968
ISSN:0924-8579
Container-title:International Journal of Antimicrobial Agents
language:en
Short-container-title:International Journal of Antimicrobial Agents

Author:

Singh Sanjay^ORCID,Gumbo Tawanda,Alffenaar Jan-Willem^ORCID,Boorgula Gunavanthi D.^ORCID,Shankar Prem,Thomas Tania A.^ORCID,Dheda Keertan,Malinga Lesibana,Raj Prithvi,Aryal Santosh,Srivastava Shashikant^ORCID

Publisher

Elsevier BV

Subject

Pharmacology (medical),Infectious Diseases,Microbiology (medical),General Medicine

Reference55 articles.

1. Gauging the impact of the COVID-19 pandemic on tuberculosis services: a global study;Migliori;Eur Respir J,2021

2. Covid-19′s devastating effect on tuberculosis care - a path to recovery;Pai;N Engl J Med,2022

3. Global Tuberculosis Report 2021,2021

4. Safety, tolerability, and pharmacokinetics of PA-824 in healthy subjects;Ginsberg;Antimicrob Agents Chemother,2009

5. Population pharmacokinetics of bedaquiline (TMC207), a novel antituberculosis drug;McLeay;Antimicrob Agents Chemother,2014

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP